bromocriptine

(redirected from Cycloset)
Also found in: Dictionary, Encyclopedia, Wikipedia.
Related to Cycloset: bromocriptine

bromocriptine

 [bro″mo-krip´tēn]
an ergot alkaloid that acts as a dopamine agonist; used as the mesylate salt to suppress prolactin secretion in the treatment of pituitary prolactinomas and of hyperprolactinemia-associated amenorrhea, galactorrhea, infertility, or male hypogonadism. It is also used as an antidyskinetic, usually in conjunction with levodopa, in the treatment of parkinsonism, and is used as a growth hormone suppressant in the treatment of acromegaly. Administered orally.

bromocriptine

/bro·mo·crip·tine/ (bro″mo-krip´tēn) an ergot alkaloid dopamine agonist, used as the mesylate salt to suppress prolactin secretion and thereby treat prolactinomas and endocrine disorders secondary to hyperprolactinemia; also used as an antidyskinetic in parkinsonism and a growth hormone suppressant in acromegaly.

bromocriptine

(brō′mō-krĭp′tēn)
n.
An ergot alkaloid, C32H40BrN5O5, that is a dopamine antagonist and is used in its mesylate form to treat Parkinson's disease, acromegaly, and excessive prolactin secretion, and to reduce the size of certain pituitary tumors.

bromocriptine

Endocrinology
An ergoline derivative which reduces pituitary prolactin secretion and size of pituitary tumours.
 
Indications
Hyperprolactinemia, pituitary tumours, amenorrhoea, female infertility, hypogonadism, acromegaly, Parkinson’s disease, neuroleptic malignant syndrome, type-2 diabetes.
 
Adverse effects
Orthostatic hypotension, vomiting, vertigo, headaches, upset stomach, coronary vasospasm, pulmonary fibrosis, hepatotoxicity.

Immunology
A dopamine D2-receptor inhibitor which inhibits T-cell-dependent induction of macrophage tumouricidal activity.

bromocriptine

An ERGOT derivative drug with DOPAMINE-like effects. It is used in the treatment of PARKINSON'S DISEASE and ACROMEGALY and given to prevent LACTATION by inhibiting the secretion of the hormone prolactin by the pituitary gland. A brand name is Parlodel.

Bromocriptine

Also known as Parlodel, the main drug used to treat galactorrhea by reducing levels of the hormone prolactin.
Mentioned in: Galactorrhea, Lactation

bromocriptine

a dopamine agonist; as a derivative of ergot alkaloids it is a luteolytic and arbortifacient which suppresses prolactin secretion and lowers plasma ACTH levels. Used as an abortifacient and in the treatment of pituitary-dependent hyperadrenocorticism.
References in periodicals archive ?
Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with CYCLOSET or any other anti-diabetes drug.
In controlled clinical trials, adverse reactions reported in 5% of patients treated with CYCLOSET and reported more commonly than in patients treated with placebo, included nausea, fatigue, dizziness, vomiting, and headache.
The Important Safety Information does not include all the information needed to use CYCLOSET safely and effectively.
VeroScience holds the New Drug Application and related technology for CYCLOSET and has a large patent portfolio that supports its preclinical and clinical development programs and product pipeline in the areas of metabolism, immunology and oncology.
Patient groups in the evaluable per protocol (EPP) population that added CYCLOSET to their treatment regimen achieved a 0.
Over six months, 35 percent of Cycloset users reached recommended average blood sugar levels, compared with 10 percent of diabetics given a dummy drug, Cincotta said.
Taken orally, once-a-day, in the morning, Cycloset provides a single brief pulse of dopamine agonist activity shortly after its administration.
is pleased to announce the recent publication of two studies in the Journal of Diabetes Research demonstrating the unique impact of Cycloset on patients living with type 2 diabetes.
The one-year study examined the effects of Cycloset compared to a placebo add-on upon incidence of adverse cardiovascular disease events and on blood glucose control.
Cycloset is the only anti-diabetes medication that may offer the potential ability to reduce this abnormal sympathetic nervous system activity.
The new analyses published in JAHA investigated 1) the impact of CYCLOSET on the ischemic cardiovascular composite endpoint of myocardial infarction, stroke, and cardiovascular death (major adverse cardiovascular events; MACE) and 2) cardiovascular death as a component of a new composite cardiovascular endpoint (myocardial infarction, stroke, hospitalization for unstable angina, hospitalization for congestive heart failure, coronary revascularization and cardiovascular death) to more critically evaluate the impact of CYCLOSET on cardiovascular outcomes in the study population.
4 million for the second quarter of 2012 included royalties on GLUMETZA net sales under the restructured commercialization agreement signed in August 2011, the gross margin split on CYCLOSET net sales, royalties on ZEGERID net sales and amortization of upfront payments.